UNITED IMMUNITY

October 1st, 2024

News

Preclinical results on the efficacy and immunogenicity of next gen COVID-19 vaccine utlizing our Myeloid Targeting PlatformTM is published.
September 2nd, 2024

News

Prof. Yvette van Kooyk Joins United Immunity’s Scientific Advisory Board
September 2nd, 2024

News

New management team launched.
July 26th, 2024

News

United Immunity enters into the Research Collaboration Agreement with AstraZeneca
July 23rd, 2024

News

A fundamental patent for a unique nanoparticle-based immune delivery system (Myeloid Targeting PlatformTM) selective for macrophages and dendritic cells is granted in Japan.
March 18th, 2024

News

United Immunity secures ￥180 million by Debt Financing from Aozora Corporate Investment
March 13th, 2024

News

United Immunity was featured in Nikkei
December 5th, 2023

News

United Immunity’s UI-102 has been selected by AMED as “Strengthening Program for Pharmaceutical Startup Ecosystem”.
November 9th, 2023

News

Preclinical study results on UI-102 will be presented at the 5th Macrophage-directed Therapies Summit.
October 19th, 2023

News

Research results regarding UI-102 will be presented at the 38st Annual Meeting of Society for Immunotherapy of Cancer (SITC).